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ABSTRACT
Our laboratory has previously reported a nonmyelosuppressive preparative regimen for hematopoietic cell
transplantation that leads to mixed chimerism and allograft tolerance in miniature swine across minor and
major histocompatibility disparities. Stable chimerism persisted in most of these animals but was restricted to
T cells and confined to peripheral blood. Because of the importance of myeloid and erythroid progenitors for
the treatment of hematologic disorders, the objective of this study was to assess whether such cells existed in
the bone marrow of these lymphoid chimeras as an indication of functional engraftment. Colony-formation
assays were performed on donor inocula before infusion and on bone marrow cells harvested from the
transplant recipients. Donor-origin myeloid/erythroid progenitor colonies were detected in bone marrow from
6 of 7 lymphoid chimeric recipients. A delayed donor leukocyte infusion successfully converted a stable
lymphoid chimera to full multilineage chimerism within 2 weeks. Donor-origin myeloid/erythroid progenitors
could be detected in the bone marrow of a host-matched recipient after myeloablation and adoptive transfer
of mobilized cells from one of the engrafted lymphoid chimeras. These data suggest that even when only
lymphoid chimerism is readily detected by flow cytometry, dormant myeloid/erythroid progenitors can exist
and subsequent conversion to full donor chimerism can be achieved. The ability to establish multilineage
engraftment and chimerism without significant toxicity may have important clinical implications for the
management of nonmalignant hematopoietic disorders and hematologic malignancies.
© 2003 American Society for Blood and Marrow Transplantation
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Our laboratory has developed a successful nonmy-
losuppressive conditioning regimen for hematopoi-
tic cell transplantation (HCT) in miniature swine
cross minor and major histocompatibility disparities
1]. Recipients are preconditioned with T-cell deple-
ion, with or without thymic irradiation and a short
ourse of cyclosporine (30-60 days), and receive high
oses of cytokine-mobilized (CM) peripheral blood
B&MTononuclear cells (PBMC), previously referred to as
eripheral blood stem cells [1]. This minimally toxic
egimen has enabled the establishment of stable mixed
ematopoietic chimerism with concomitant induction
f donor-speciﬁc tolerance and long-term acceptance
f MHC-disparate renal allografts [1,2]. However,
everal of our hematopoietic recipients have shown
eripheral blood chimerism proﬁles that consist pri-
arily of donor-origin T cells with myeloid chimer-peripheral blood
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ism below the level of detection by ﬂow cytometry
[3,4]. To extend this minimally toxic conditioning
regimen to the management of hemoglobinopathies
and other hematologic disorders, functional multilin-
eage progenitor cell engraftment must be achieved. In
this study, we examined the myeloid/erythroid pro-
genitor cell content and hematopoietic potential of
the donor CM-PBMC inocula by using colony for-
mation and cobblestone area-forming cell (CAFC)
assays. We also determined the extent of recipient
engraftment via polymerase chain reaction (PCR)
analysis of myeloid/erythroid progenitor cell colonies
harvested from the bone marrow (BM) of these lym-
phoid chimeric recipients.
MATERIALS AND METHODS
Animals
Transplant donors and recipients were selected
from our herd of Massachusetts General Hospital par-
tially inbred, major histocompatibility complex
(MHC)–deﬁned miniature swine [5,6]. The animals
used in this study were derived from herds bred in-
tentionally to avoid further inbreeding of background
genes so that they differ by multiple minor histocom-
patibility loci. CM-PBMC donors were 4 to 8 months
old and weighed 30 to 50 kg. Recipients were 8 to 12
weeks old and weighed 5 to 15 kg. Donors were
chosen to be positive and recipients negative for the
allelic marker pig allelic antigen (PAA) [7].
Conditioning Regimen for CM-PBMC Infusion
The protocol used for nonmyelosuppressive, allo-
geneic CM-PBMC infusion has been described in
detail previously [1]. Five of the 7 hematopoietic re-
cipients were treated with 7 to 10 Gy of thymic irra-
diation, and 2 recipients received no thymic irradia-
tion (Table 1). All recipients were given 0.05 mg/kg
pCD3-CRM9 [8] on day 2. CM-PBMC was col-
lected by leukapheresis from donor animals treated for
5 to 7 days with recombinant porcine interleukin
(IL)–3 (100 g/kg) and recombinant porcine stem cell
factor (pSCF; 100 g/kg; both from BioTransplant,
Boston, MA). Enteral cyclosporine (CyA; Neoral; No-
vartis Pharmaceuticals, East Hanover, NJ) was admin-
istered for 30 to 60 days beginning on day 1, with
dosages adjusted to maintain serum CyA levels be-
tween 700 and 800 ng/mL for the ﬁrst 15 to 30 days
of treatment and gradually tapering thereafter. One
animal (no. 14422) received myeloablative condition-
ing consisting of 1000 cGy of whole-body irradiation
delivered in 2 split doses on day 1 and day 0. This
animal then underwent transplantation on day 0 with
20  108 CM-PBMC per kilogram from a lymphoid
chimera (no. 13272) of the same native SLA haplo-
type.
Flow Cytometry Analysis
Chimerism detection in recipients of allogeneic
CM-PBMC by using ﬂow cytometry has been de-
scribed previously [1]. Flow cytometry was performed
with a Becton Dickinson (San Jose, CA) FACScan.
The following porcine-speciﬁc antibodies were used
to monitor depletion and recovery of circulating cells
in each recipient after T-cell depletion and CM-
PBMC infusion: wCD3 898H2-6-15 (mouse immu-
noglobulin [Ig]G2aK) [9], CD3a BB23-8E6 (mouse
IgG1), CD5 BB6-9G12 (mouse IgG1) [10], SWC3-
myeloid 74-22-15 (mouse IgG1K), and PAA 1038H-
10-9 (mouse IgMK) [7]. Two-color staining was rou-
tinely performed in multiple tubes by using
ﬂuorescein isothiocyanate (FITC)–conjugated CD3,
CD4, CD8, and SWC3a versus biotinylated PAA and
versus the biotinylated 12.2.2 as a negative isotype
(IgMK)–matched control, followed by phycoerythrin
streptavidin. Chimerism was considered below the
level of detection by ﬂow cytometry when the PAA
staining did not differ signiﬁcantly from the back-
Table 1. CM-PBMC Infusions Contain High Levels of Hematopoietic Progenitor Cells
CM-PBMC
Recipient
SLA
Mismatch
Thymic
Irradiation
CM-PBMC Infusion
CM-PBMC
 108/kg
CFU-GEMM
106/kg*
CAFC 
106/kg†
13101 ac3ad 10 Gy 200 6.53 ND
13272 ac3ad 10 Gy 150 9.4 ND
13476 cd3ad 7 Gy 150 2.5 ND
13635 cd3ad 10 Gy 150 3.75 ND
14040 ac3ad 10 Gy 150 10.31 3.45
14225 ac3ad None 150 4.89 6.79
14143 cc3dd None 150 1.66 1.12
ND indicates not done.
*CFU analysis was performed on the cytokine-mobilized donor inocula for all animals that underwent transplantation.
†CAFC analysis was performed only for the animals that more recently received transplants: 14040(donor 13666), 14225 (donor 13471), and
14143 (donor 13901). Figure 1 shows consistency in frequency of CAFC in day 5, 6, and 7 leukapheresis product for 7 different mobilized
donors, 3 of which were donors for recipients included in this study.
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ground isotype-matched control (12.2.2) staining for
each 2-color tube. Peripheral blood chimerism was
considered detectable if the percentage of PAA stain-
ing was at least twice the background staining seen
with the isotype-matched control monoclonal anti-
body. Background staining typically ranged from
0.2% to 0.8%. Myeloid chimerism was considered
below the limit of detection when the percentage of
double-stained cells with FITC SWC3a versus phy-
coerythrin streptavidin (PESA)/biotin PAA was less
than twice the percentage seen with double-staining
with FITC SWC3a versus PESA/biotin 12.2.2. The
percentage of PAA-positive cells among lymphocytes,
monocytes, and granulocytes is plotted on the chimer-
ism proﬁle graphs in each of the ﬁgures. Although
myeloid chimerism could be detected by ﬂow cytom-
etry at signiﬁcant levels early on in every recipient, it
waned over time until it could no longer be reliably
detected above background by ﬂow cytometry.
Colony Formation Assays
These in vitro progenitor cell assays were per-
formed according to methods described previously
[11,12]. Brieﬂy, mononuclear cells from leukapheresis
product or BM biopsy were plated at concentrations
of 25,000 cells in 35-mm petri dishes (Nunc, Naper-
ville, IL) in a total volume of 1.5 mL of methylcellu-
lose-based medium (Methocult H4230; Stem Cell
Technologies, Vancouver, British Columbia, Canada)
supplemented with 11 ng/mL recombinant pSCF,
0.85 ng/mL recombinant porcine IL-3 (pIL-3), 2
ng/mL recombinant porcine granulocyte macrophage
colony-stimulating factor, and 0.85 U/mL recombi-
nant human erythropoietin (Amgen Inc., Thousand
Oaks, CA). After 10 to 14 days of incubation in 5%
CO2 at 37°C, each culture dish was visually scored
through an inverted microscope and evaluated for the
presence of blast-forming unit–erythroid (BFU-E),
colony forming unit–granulocyte, monocyte (CFU-
GM), and colony forming unit–granulocyte, erythroid,
megakaryocyte, monocyte (CFU-GEMM). Only col-
onies containing50 cells were counted and classiﬁed
on the basis of morphology.
CAFC Assay
The CAFC assay is based on a previous method of
Breems et al. [13] described for human BM cells,
except that we cultured in the presence of recombi-
nant porcine cytokines. Cell suspensions were plated
over a series of dilutions in 96-well plates (16 wells per
dilution with six 2-fold dilution steps) on a pre-estab-
lished conﬂuent murine stromal cell line (initially
derived from C57BL/6 mouse BM) and cultured at
37°C and 5% CO2 for 6 weeks in medium consist-
ing of Iscove’s modiﬁed Dulbecco’s medium with
GlutaMAX-1 (Invitrogen, Carlsbad, CA) supplemented
with 25 ng/mL pSCF, 2 ng/mL pIL-3, gentamicin
(100 g/mL), 2-mercaptoethanol (104 mol/L), 12.5%
fetal bovine serum, 12.5% horse serum, and hydro-
cortisone (106 mol) at 37°C and 5% CO2 for 6
weeks. The percentage of wells with at least 1 phase-
dark hematopoietic clone of at least 5 cells (ie, cob-
blestone area) beneath the stromal layer was deter-
mined weekly. Frequencies of the week 6 CAFC
subsets were calculated with Poisson statistics as pre-
viously described [14].
PCR for Detection of Donor-Derived
Hematopoietic Progenitors
After colony formation assays (described previ-
ously), individual progenitor colonies derived from
recipient BM were resuspended into normal saline and
pelleted, and the saline was aspirated before immedi-
ate lysis or storage at 70°C for later analysis. DNA
lysates from individual or pooled (10 colonies) my-
eloid progenitor colony pellets were prepared as de-
scribed previously [15] by the addition of 40 L of
lysis buffer (10 mM Tris-HCl [pH 8.3], 50 mM KCl,
0.45% Tween-20, 0.45% NP-40, and 100 g/mL
proteinase K), followed by digestion for 60 minutes at
55°C. The proteinase K was denatured by an addi-
tional 10-minute incubation at 100°C, and 12.5 L of
this DNA lysate was used for PCR ampliﬁcation.
Genomic DNA control templates were extracted from
whole blood of SLAAA, SLACC, and SLADD miniature
swine by using the QIAamp Blood Kit (Qiagen Inc.,
Valencia, CA). In each PCR reaction, 200 ng of
genomic DNA was ampliﬁed in a 50-L reaction
mixture containing 0.2 M of each primer (described
below), 1Qiagen PCR Buffer (with 15 mMMgCl2),
1.25 U Qiagen Hot Star Taq Polymerase (5 U/L),
and 0.2 mM of each deoxynucleoside triphosphate
(PerkinElmer). Ampliﬁcation reactions were per-
formed with a PTC-100 Programmable Thermal
Controller (MJ Research Inc., Watertown, MA) under
the following conditions: template denaturation at
94°C for 15 minutes with 45 cycles of melting at 94°C
for 15 seconds, annealing at 53°C for 15 seconds, and
extension at 72°C for 30 seconds, followed by a ﬁnal
extension at 72°C for 10 minutes.
The following oligonucleotide primers were used
in PCR analyses: no. 136 (5-CACTCCCTGAGC-
TATTTC-3), no. 138 (5-GCTCTGGTTGTAG-
TAGCC-3), and no. 146 (5-GTGTCCCTTTG-
TATCTGTGTC-3). The primer combination 136/
138 ampliﬁed a 254-base pair (bp) segment of the SLA
class I gene common to the A, C, and D SLA haplo-
types (SLA class Iall). The primer combination 136/
146 ampliﬁed a 199-bp segment of the SLA class I
gene unique to the SLAC haplotype (SLA class Ic). All
donor-recipient animal combinations were chosen
such that the donor was either heterozygous or ho-
mozygous for the SLAC haplotype, whereas the recip-
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ients contained only SLAA or SLAD haplotype com-
binations. For each genomic control and experimental
sample, 2 PCR reactions were run in parallel: 1 with
the 136/138 and the other with the 136/146 primer
combination. The results reported on the detection of
donor-derived myeloid progenitors include only those
experimental samples with demonstrable ampliﬁcation
of the SLA class Iall region. Southern blots of 136/146
ampliﬁcation products were also performed via hy-
bridization to an internal oligonucleotide probe. Au-
toradiographs of the Southern blots are shown in the
ﬁgures.
RESULTS
Functional Peripheral Blood Hematopoietic
Progenitor Cells after Cytokine Mobilization
Donor animals were treated for 5 days with por-
cine-speciﬁc cytokines, pIL-3 and pSCF, which
achieve high yield mobilization of progenitor cells
into the peripheral blood, as described previously
[11,12,15]. All animals tolerated the cytokine treat-
ments well, with no adverse effects or clinical compli-
cations. Leukapheresis products were collected on
days 5, 6, and 7. The frequency of pluripotent hema-
topoietic progenitors (CFU-GEMM) per total nucle-
ated cell collected on each day of leukapheresis was
quantitatively determined by colony-formation assays.
Limiting-dilution CAFC assays [13] were initiated on
the CM-PBMC collected on each day of pheresis [16].
The relative frequencies of CFU-GEMM and CAFC
per 105 total nucleated cells in BM and in unmobilized
and CM leukapheresis product were calculated (Fig-
ure 1). Shown are results from 7 different representa-
tive donors, where both CFU and CAFC analysis were
performed. Three of these donors (bold) were used for
3 of the 7 transplant recipients included in this study
(recipients are shown in parentheses). By the ﬁfth day
of cytokine treatment, all cytokine-treated donor an-
imals had peripheral levels of CFU-GEMMs ranging
between 10 and 100/105 total nucleated cells, a 10-
fold increase in frequency compared with the range
found in unmobilized leukapheresis product (Figure
1A). A more pronounced augmentation was noted in
the week 6 subset CAFC frequency after cytokine
therapy when compared with unmobilized pheresis
product (Figure 1B). These levels were comparable
with those observed in whole BM. One animal (no.
13471) exhibited CAFC frequencies in mobilized
pheresis product that approached levels 100-fold
greater than unmobilized pheresis product and 10-
fold greater than BM. The quantity of CFU-GEMM
and CAFC infused into the recipient animals included
in this study ranged between 1.7 and 10.3  106/kg of
recipient and 1.1 to 6.8  106/kg of recipient, respec-
tively (Table 1).
Figure 1. Comparative analysis of hematopoietic progenitor cell content in BM and cytokine-mobilized and -unmobilized leukapheresis
product in miniature swine. Donor mobilization with the porcine cytokines SCF and IL-3 occurred on days 0 to 8. A, Increased frequency of
pluripotent progenitors (CFU-GEMM) in the peripheral blood of mobilized donors compared with unmobilized leukapheresis product. B,
High levels of multipotent (functional) hematopoietic progenitors (CAFC) found in mobilized leukapheresis product compared with levels
found in unmobilized leukapheresis product and BM. Shown are results from 7 different representative donors in which both CFU and CAFC
analysis were performed. Three of these donors (bold) were for 3 of the 7 transplant recipients included in this study (recipients are shown in
parentheses).
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Persistent Lymphoid Chimerism after Allogeneic
HCT without Myelosuppressive Conditioning
As shown in Table 1, 1.5 to 2  1010/kg mono-
nuclear cells were infused into each conditioned re-
cipient, across haploidentical (n  6) and 2-haplotype
(n  1) major histocompatibility mismatches. Two
recipients, no. 14143 and no. 14225, did not receive
thymic irradiation as part of the preparative regimen.
The leukapheresis product contained between 30%
and 50% CD3-positive cells, as determined by ﬂow
cytometric analysis (data not shown). High levels of
multilineage peripheral blood chimerism was ob-
served among these 7 recipients in the immediate
posttransplantation period, with a gradual decline to
undetectable levels of myeloid chimerism by ﬂow cy-
tometry over time. Stable levels of lymphoid chimer-
ism were then maintained for at least 100 days in all
animals except for no. 14040. Animal no. 14040 lost
detectable lymphoid as well as myeloid chimerism by
ﬂow cytometry by day 29.
Detection of Donor-Derived Myeloid Progenitors
in the BM of Lymphoid Chimeric Animals
Given the variable detection of myeloid chimerism
by ﬂow cytometry observed at later time points in
these HCT recipients, we sought to determine
whether myeloid hematopoietic progenitors had gen-
uinely engrafted in these lymphoid chimeras. BM cells
were harvested from lymphoid chimeric recipients and
plated in methylcellulose cultures supplemented with
growth factors that favor proliferation of myeloid pro-
genitor colonies (CFU-GEMM, CFU-GM, and
BFU-E). After a 10- to 14-day incubation period,
these colonies were picked and subjected to PCR
analysis either individually or in pools of 10 by using
primers speciﬁc for the SLA class Ic gene, which was
present only in the hematopoietic donors. Southern
blot analyses with an SLA class Ic-speciﬁc oligonucle-
otide probe were also performed. A summary of the
results obtained from PCR analysis of progenitor cell
colonies in each of the HCT recipients is provided in
Table 2.
Six of 7 recipients of MHC-mismatched CM-
PBMC infusions showed evidence of donor-derived
myeloid/erythroid progenitor colonies despite a lack
of detectable myeloid chimerism in the periphery by
ﬂow cytometry. A sample autoradiograph shown in
Figure 2 depicts multiple SLA class Ic–positive CFU-
GM, BFU-E, and CFU-GEMM colony pools of vary-
ing intensity from one of the lymphoid chimeric re-
cipients (no. 13476) 590 days after HCT. PCR
analysis of recipient 14040, which had no detectable
lymphoid or myeloid chimerism in the peripheral
blood at the time of BM biopsy, yielded 1 positive
pool of progenitor colonies among 20 pools of 10
analyzed (Figure 3). Animal 14143 showed no evi-
dence of myeloid or erythroid engraftment by this
technique (Figure 4). A total of 310 progenitor colo-
nies in pools of 10 were analyzed from animal 14143,
including 18 pools of CFU-GM colonies, 6 pools of
Table 2. Hematopoietic Progenitor Cell Engraftment in HCT Recipients
Animal Irradiation
% Donor
Myeloid Cells
Detected at
Time of BM
Biopsy*
BM Biopsy
Day(s) after
HCT for
CFU Analysis
Donor-Type SLA Class Ic—Positive
Myeloid Progenitor Colony Pools†
Donor-Derived
Myeloid
Progenitors
DetectedCFU-GM BFU-E CFU-GEMM
13101 before DLI 10 Gy TI <1 709 1/30 0/18 1/4 
13101 after DLI 99 742 17/18 19/19 4/4 
13272 10 Gy TI Undetectable 1022 16/34 2/42 1/8 
13476 7 Gy TI Undetectable 590 6/6 2/2 2/2 
13635 10 Gy TI Undetectable 264 4/4 3/3 3/3 
14040 10 Gy TI Undetectable 115 and 224 2/19 1/9 3/8 
14225 None Undetectable 263 2/4 1/3 0/1 
14143 None Undetectable 132 and 233 0/18 0/7 0/6 
14422 (SLAad) (adoptively
transferred with CM-
PBMC from 13272)
10 Gy WBI Undetectable 30 and 482 2/9 1/8 1/5 
Negative controls
14178 (SLAad) None Undetectable 98 0/50 0/30 0/10 
14495 (SLAdd) NA NA NA 0/70 0/30 0/10 
 10% SLAcc T cells NA NA NA 0/70 0/40 0/10 
NA indicates not applicable; TI, thymic irradiation; WBI, whole-body irradiation.
*Based on ﬂow cytometry of peripheral blood (see Materials and Methods). For animals 14422 and 14178, donor-derived refers to the original
donor cells from the chimeric animal 13272.
†Pools of 10 colonies were picked for CFU analysis for all animals except animal 13101. Individual colonies were picked and analyzed from
animal 13101 before and after DLI. The numbers of positive colonies out of the total number of colonies picked (individual or pools of 10)
are shown.
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CFU-GEMM colonies, and 7 pools of BFU-E colo-
nies. Animal 14143 was 1 of the 2 animals that did not
receive thymic irradiation as part of the conditioning
regimen.
Experiments were performed to determine
whether circulating T cells of donor origin, the pat-
tern of chimerism commonly observed in most of our
hematopoietic recipients, could account for the detec-
tion of donor-derived progenitors in the BM in these
animals. T cells isolated from PBMC of an SLACC-
naive animal were directly added to the BM cell cul-
ture of an SLADD-naive animal (no. 14495) at a pro-
portion of 10%. No SLA class Ic–positive signals were
detected by PCR analysis of 120 progenitor cell col-
onies derived from this culture (Figure 5 and Table 2).
These results support the conclusion that detection of
donor class Ic–positive myeloid progenitors in T-cell
chimeric animals was not simply due to detection of
circulating chimeric T cells found in the BM prepa-
ration. This is further supported by the ﬁnding that no
SLA class Ic–positive signals were detected out of 310
colonies analyzed from animal 14143, an animal with
7% donor class Ic–positive peripheral blood lymphoid
chimerism at the time of BM biopsy. Additionally, a
PAA-negative animal (no. 14178) matched to the na-
tive haplotype of a long-term chimeric recipient (no.
13272) was infused with unmobilized leukapheresis
product from this chimera and monitored by ﬂow
cytometry. T cells from the original CM-PBMC do-
nor (PAA positive; SLA class Ic positive) were detect-
able at a level of 2% in this animal’s circulating cells
and became undetectable by day 3 (data not shown).
No SLA class Ic–positive BM-derived progenitor col-
ony pools were subsequently detected in this animal
by PCR analysis (Figure 5 and Table 2).
Multilineage Progenitor Cell Engraftment and
Conversion to Full Chimerism
A donor leukocyte infusion (DLI) was performed
in one of the haploidentical HCT recipients (no.
13101) whose original hematopoietic cell donor was
still alive. The DLI consisted of unmobilized PBMC
containing 5  107 T cells per kilogram of recipient.
Animal 13101 converted to full donor chimerism
within 2 weeks after a DLI from the original hema-
topoietic donor (Figure 6). The proportion of donor-
derived myeloid progenitors increased from 1.9%
(1/52 colonies) before DLI to 97.6% (40/41 colonies)
after DLI (Table 2). Graft-versus-host disease
(GVHD) occurred in this animal in the ensuing weeks
after conversion to full chimerism; it was marked by
an exfoliative rash and transient neutropenia. The
animal remained clinically stable with only minimal
immunosuppressive therapy. The clinical course of
this recipient was complicated further by severe os-
Figure 2. Multilineage progenitor cell engraftment in lymphoid chimeras. A, Fluorescence-activated cell sorter analysis depicting the
peripheral blood chimerism proﬁle observed after haploidentical HCT. Persistent mixed hematopoietic chimerism (600 days) restricted
primarily to T cells is shown, with low to undetectable levels of myeloid chimerism by day 100. *Day of BM biopsy for colony assays. B,
Representative autoradiograph depicting multiple SLA class Ic–positive myeloid progenitor colony pools (10 colonies) from BM (day 590) of
a haploidentical hematopoietic recipient.  indicates no DNA template. C and D, Genomic DNA controls from SLAcc (positive control) and
SLAdd (negative control) pigs, respectively.
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teomyelitis, and the animal was killed nearly 100 days
after DLI.
As an approach to conﬁrm donor multilineage
progenitor cell engraftment in animal 13272, we re-
constituted a naive, myeloablated animal (no. 14422)
of the same native SLA haplotype, SLAAD, with CM-
PBMC taken from animal 13272 at day 851 after
HCT. Figure 7A shows the chimerism proﬁle of an-
imal 13272 during cytokine mobilization and before
HCT into animal 14422. As shown in Figure 7B,
animal 14422 reconstituted 7 days after hematopoietic
transplantation, with 90% of the circulating mono-
nuclear cells of no. 13272 host origin (PAA negative,
SLA class Ic negative) and nearly 2% of no. 13272
donor origin (PAA positive; SLA class Ic positive).
Cells harvested from a day 30 BM biopsy revealed 1
SLA class Ic–positive pool of erythroid progenitor
colonies (data not shown). An additional BM sample
taken from animal 14422 at the time of death 482 days
after transplantation with no. 13272 CM-PBMC re-
vealed 7 of 16 class Ic–positive pools, presumably de-
rived from donor-type progenitors engrafted in the
original lymphoid chimera (Figure 7C). These results
are also summarized in Table 2.
DISCUSSION
Partially inbred MHC-deﬁned miniature swine
provide a unique large-animal model in which most of
the transplantation combinations relevant to human
transplantation can be performed. The animals used
in this study were derived from herds bred intention-
ally to avoid further inbreeding of background genes,
so that they continue to differ by multiple minor
histocompatibility loci. Transplantations within a
herd simulate transplantations between HLA-identi-
cal siblings; transplantations between completely
MHC-disparate herds resemble cadaveric or non-
matched sibling transplantations; and transplantations
between single haplotype-mismatched heterozygotes
(eg, SLAac 3 SLAad) resemble parent into offspring
or 1 haplotype–mismatched sibling transplants.
The results obtained in this study indicate that
multilineage progenitor cell engraftment across MHC
barriers can occur with a minimally toxic nonmyelo-
suppressive conditioning regimen. Quiescent myeloid
progenitor cell engraftment can exist despite unde-
tectable myeloid chimerism in the peripheral blood by
ﬂow cytometry. The quiescent status of these en-
grafted progenitor cells is similar to that observed
after stem cell transplantation in rodent models [17].
Hematopoietic stem cells capable of long-term en-
graftment are thought to be generally quiescent
[18,19]. The mechanism of homing of transplanted
stem cells to the host BM and the fate of these cells
after transplantation is an active area of investigation
[20,21].
A key feature of this preparative regimen may be
high-dose infusions of CM-PBMC enriched with he-
matopoietic progenitors, enabling sufﬁcient engraft-
Figure 3. Progenitor cell en-
graftment and tolerance with-
out chimerism. This animal (no.
14040) received a haploidentical
HCT. *Day of BM biopsy for
colony assays. A, Fluorescence-
activated cell sorter analysis of
the peripheral blood demon-
strated loss of hematopoietic
(macro-) chimerism by day 30.
B, Despite a lack of peripheral
blood chimerism in any lineage,
PCR analysis revealed evidence
of microchimerism in the BM.
The autoradiograph shows the
existence of 1 of 20 (donor-
type) SLA class Ic–positive
pools of myeloid progenitor cell
colonies (BFU-E) harvested
from a BM biopsy performed
on day 115.
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ment without myeloablation [22,23]. In this study, we
show the degree of progenitor cell enrichment and
content of these mobilized mononuclear cell infu-
sions. In studies performed in DLA-identical and hap-
loidentical dogs, myelosuppression through whole-
body irradiation was determined to be required for
Figure 4. T-cell chimerism without progenitor cell engraftment. A, Peripheral blood chimerism proﬁle of animal 14143. *Day of BM biopsy
for colony assays. B, PCR analysis performed on BM cells harvested at day 132 after HCT reveal no donor-derived myeloid progenitors
detectable among 18 colony pools (14 CFU-GM and 4 BFU-E), despite the presence of T-cell chimerism in the periphery at the time of BM
biopsy. () indicates a positive control consisting of 1 SLA class Ic–positive myeloid progenitor cell (CFU-GM) colony combined with 9 SLA
class Ic–negative colonies.
Figure 5. Exogenously added SLA class Ic (donor-type)–positive T cells to SLA class Ic–negative BM cells in methyl cellulose cultures does
not result in the detection of donor-type myeloid progenitor cell colonies. Autoradiograph of genomic DNA controls with BM-derived
myeloid progenitor cell colony pools from SLA class Ic–negative pigs 14495 (SLAdd) and 14178 (SLAad). Peripheral blood T cells from an
SLAcc animal were added to the BM culture from no. 14495 at a proportion of 10% before plating. No SLA class Ic–positive colonies were
detected out of 120 analyzed. Animal 14178 was an unconditioned recipient of PBMC from the mixed chimera (no. 13272) with 10% lymphoid
chimerism and undetectable myeloid chimerism in the periphery at the time of transplantation. No SLA class Ic–positive colony pools were
detected from the BM of animal 14178 out of 90 colonies analyzed.
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engraftment [24]. The fact that the quantity of CM-
PBMC and CFU-GEMM infused in swine was ap-
proximately 1 to 2 orders of magnitude greater than
that used for dogs [25] (Table 1) may explain the
apparent discrepancy between the 2 models. Fre-
quency analyses of week 6 CAFC subsets in our mo-
bilized donors yielded high levels of functional pro-
genitors that were comparable to those observed in
previous studies evaluating the quality of mobilized
leukapheresis product from cancer patients and nor-
mal healthy donors [16,26].
Conversion to full donor chimerism across mHA
differences has been previously reported in canine
mixed chimeras after nonmyeloablative HCT and
subsequent adoptive immunotherapy with mHA-sen-
sitized DLI [27]. We show here, for the ﬁrst time in a
preclinical large-animal model, conversion to full he-
matopoietic chimerism across a complete (haploiden-
tical) MHC mismatch with nonmyelosuppressive
HCT followed by infusion of donor leukocytes (Fig-
ure 6). DLI consisted of unfractionated PBMC from
the original hematopoietic donor at a dose that con-
tained 5  107 T cells per kilogram. Although we
cannot be absolutely sure that the conversion to com-
plete chimerism arose from preexisting engrafted pro-
genitors rather than from progenitors present in the
DLI, we believe that the former is more likely. The
level of myeloid progenitors present in unmobilized
leukapheresis product is extremely low (Figure 1). In
addition, we have found that a similar dose of DLI is
not effective when it is given to chimeric animals that
do not show evidence of myeloid engraftment by PCR
of CFUs (data not shown). Adoptive transfer of do-
nor-derived myeloid progenitors from long-term chi-
meric animal 13272 into a lethally irradiated second-
ary recipient (no. 14422) provided further evidence
that myeloid progenitor cell engraftment can occur
without myelosuppressive conditioning.
We have observed a low incidence of GVHD after
SLA-haploidentical HCT when recipients were con-
ditioned with T-cell depletion and CyA either with or
without thymic irradiation. All animals included in
this study underwent transplantation across a full
MHC barrier, yet only 1 animal developed any clinical
signs of GVHD during the course of the experiment.
This is not typical of SLA-haploidentical BM trans-
plantation after lethal whole-body irradiation in min-
iature swine. With use of fractionated high-dose
whole-body irradiation as the preparative regimen,
100% of animals who underwent transplantation
across an SLA-haploidentical barrier developed severe
and often lethal GVHD [28,29]. There is some evi-
dence suggesting that CyA may be playing a role in
GVHD prevention in our nonmyelosuppressive
model. Natural killer cells may also play a role in
controlling GVHD in this model [30], particularly
given that none of the agents administered have nat-
ural killer–speciﬁc effects. We are currently investi-
gating the mechanism of GVHD prevention in this
model.
Animal 13101 developed GVHD within 3 days
after cessation of CyA on day 30. GVHD in this
Figure 6. Conversion to full chimerism after DLI in animal 13101.
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animal may have contributed to the very high degree
of long-term stable chimerism present in this animal.
GVHD completely resolved spontaneously with no
additional treatment by day 90 and then recurred after
DLI given on day 710. Although skin manifestations
seemed to be resolving after a brief course of low-dose
steroid therapy initiated after DLI, the clinical condi-
tion of this animal became acutely compromised with
the development of osteomyelitis. GVHD compli-
cated this clinical course but was not likely the pri-
mary cause of death. In the future, early aggressive
immunosuppressive treatment of GVHD may avoid
these complications.
A number of factors may contribute to the persis-
tence of lymphoid and not myeloid chimerism under
this regimen of HCT. One explanation could be the
persistence of donor-origin T cells from the initial
donor inoculum. Studies of T-cell life spans in hu-
mans have revealed that human memory cells may
have an average life span of approximately 35 years
[31]. A pertinent example in this study is that of
recipient 14143, who exhibited T-cell chimerism but
did not show engraftment of myeloid progenitors
(Figure 4). Therefore, these donor-origin T cells may
not have been indicative of engraftment and could
have actually have been derived from the initial CM-
PBMC infusion. We are currently investigating the
nature and origin of persisting T cells in long-term
chimeric animals in this model.
Animal 14143 was 1 of the 2 animals that did not
receive thymic irradiation as part of the conditioning
regimen. It is unclear, however, whether the lack of
thymic irradiation contributed to the lack of evidence
of engrafted myeloid progenitor cells in the BM. The
other animal that did not receive thymic irradiation,
animal 14225, did have evidence of myeloid/erythroid
engraftment 263 days after HCT at a time when
peripheral myeloid chimerism was undetectable by
ﬂow cytometry (Table 2).
Although not evaluated in this study, the CM-
PBMC infusions may have contained higher levels of
lymphoid compared with myeloid progenitors, thus
favoring lymphoid engraftment and increased levels of
lymphoid descendants in the periphery. The existence
of an early lymphoid-committed stem cell, with dif-
ferentiation potential skewed toward lymphoid lin-
eages, has been previously described [32-34]. It is
possible that cytokine treatment with SCF and IL-3
may preferentially mobilize this progenitor cell pop-
ulation in donor animals. Alternatively, these lym-
phoid-committed stem cells may have enhanced self-
renewal potential compared with myeloid progenitors,
given the known heterogeneity of this property among
different progenitor cell populations [32]. Several
groups have also reported that CM hematopoietic
progenitors are at various stages of maturation [26]
and uniformly in the G1 or G0 phases of the cell cycle
[32]. This quiescent state intrinsic to mobilized pro-
genitors infused into these recipients may contribute
to the lack of detectable myeloid chimerism. As ob-
Figure 7. Adoptive transfer of donor-origin myeloid progenitors
from a haploidentical HCT recipient with primarily lymphoid chi-
merism (13272) into an SLA haplotype–matched recipient (14422)
preconditioned with lethal radiation (500 Gy 2). A, Fluorescence-
activated cell sorter analysis depicting the peripheral blood chimer-
ism proﬁle of animal 13272. After mobilization with cytokines on
days 847 to 851, PBMC from this mixed chimeric animal were
infused into a myeloablated recipient (no. 14422). B, The absolute
number of lymphocytes of each origin (13272 donor-type, 13272
host-type, and 14422 host-type) present in the peripheral blood
after lethal irradiation and reconstitution is shown. A population of
13272 donor-type (PAA positive and SLA class Ic positive) cells can
be clearly detected after adoptive cell transfer. C, Autoradiograph of
Southern blot analysis of progenitor colonies harvested from a day
482 BM biopsy revealed 2 of 4 GM colonies, 4 of 4 GEMM
colonies, and 1 of 4 BFU-E colonies derived from the original
CM-PBMC donor (SLA class Ic positive) of the mixed chimera.
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served in the mixed chimera that converted to full
donor chimerism (Figure 6), the creation of more
hematopoietic niches, such as with a DLI, could pro-
vide a sufﬁcient stimulus or competitive advantage to
enable propagation of the scarce donor-derived my-
eloid progenitors already engrafted. Alternatively,
DLI may increase the threshold of engraftment by
improving cell migration and homing of progenitor
cells to the BM microenvironment [35]. We are con-
tinuing these adoptive immunotherapeutic approaches
to convert our HCT recipients to full donor chimeras.
Compared with nonmyelosuppressive condition-
ing, myeloablative and myelosuppressive approaches
to HCT may create more hematopoietic niches for
donor cells to engraft and may lead to higher levels of
peripheral myeloid chimerism [36,37]. It is possible
that the lack of available myeloid niches after nonmy-
elosuppressive conditioning may represent another
likely reason for the general lack of myeloid chimer-
ism in these HCT recipients, although this is not a
generally accepted hypothesis [38]. However, within
the context of patients with hemoglobinopathies, de-
fective myeloid lineages may not effectively compete
with cells from a healthy donor, and, thus, increased
myeloid engraftment and chimerism may be observed
without myelosuppression even before DLI in these
patients. This is consistent with murine studies sug-
gesting that quiescent donor progenitor cells can exist
in minimally conditioned recipients of BM transplan-
tation and that these quiescent cells are capable of
contributing to hematopoiesis when given a compet-
itive advantage [39,40].
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